Stock SRPT SAREPTA THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up
PDF Report

News Sarepta Therapeutics, Inc.

Equities

SRPT

US8036071004

Delayed Nasdaq
Other stock markets
 04:00:00 2023-10-02 pm EDT 		Intraday chart for Sarepta Therapeutics, Inc. 5-day change 1st Jan Change
118.59 USD -2.17% +3.36% -8.48%
Sep. 11 Transcript : Sarepta Therapeutics, Inc. Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-11-2023 08:40 AM CI
Aug. 30 Quest Diagnostics Says FDA Grants Breakthrough Designation for Test to Aid in Duchenne Muscular Dystrophy Therapy MT

Summary

Research
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
Scheduling Order Issued In REGENXBIO v. Sarepta Litigation
AQ
Transcript : Sarepta Therapeutics, Inc. Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-11-2023 08:40 AM
CI
Sarepta Therapeutics Announces Recipients of the 6th Annual Route 79, The Duchenne Scholarship Program, for the 2023-2024 Academic Year
BU
Sarepta Therapeutics to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
BU
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)
AQ
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BU
Quest Diagnostics Granted FDA Breakthrough Designation for its Adeno-associated virus Test
AQ
Quest Diagnostics Says FDA Grants Breakthrough Designation for Test to Aid in Duchenne Muscular Dystrophy Therapy
MT
Quest Diagnostics Granted FDA Breakthrough Designation for its Adeno-associated virus (AAV) Test
PR
Sarepta Therapeutics Makes Strategic Investment in Lexeo Therapeutics
MT
Lexeo Therapeutics, Inc. Announces Strategic Investment from Sarepta Therapeutics to Support Development of Lexeo?S Cardiovascular Gene Therapies
CI
Lexeo Therapeutics, Inc. announced that it has received funding from Sarepta Therapeutics, Inc.
CI
UC Davis first in the state to offer life-changing therapy for Duchenne Muscular Dystrophy
AQ
Sarepta And Catalent File Answers In REGENXBIO v. Sarepta Litigation
AQ
Insider Buy: Sarepta Therapeutics
MT
Insider Buy: Sarepta Therapeutics
MT
Insider Buy: Sarepta Therapeutics
MT
Insider Sell: Sarepta Therapeutics
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features

Filters

Announcement Date

Since

Until

  1. Markets
  2. Equities
  3. Stock Sarepta Therapeutics, Inc. - Nasdaq
  4. News
Discover our Free Content to Help You Better Understand the Stock Market.
100% Free Registration
fermer